Pilot — not validated. Eligibility suggestions must be confirmed with the Clinical Research Coordinator before any enrollment decision. For Moffitt providers only. Most tested on GI cancers — Thoracic and Head & Neck trials are included but less tested.
Avoid pasting patient identifiers. ⌘↵ to search.
Example: a physician describes a 58-year-old with metastatic pancreatic adenocarcinoma that progressed on gemcitabine and nab-paclitaxel. The screener reads it as second line, the physician answers KRAS G12D present, and the list narrows to the KRAS G12D trial shown first.
Describe the patient
Type or paste the case in your own shorthand — diagnosis, stage, prior therapy, biomarkers, ECOG. No identifiers.
Check what was understood
The reply restates the case. Cancer type and line of therapy are chips: click one to correct it.
Refine
Add a detail in plain words, or answer the molecular questions — each answer re-ranks the list at once.
Review and contact the CRC
Each card marks every criterion. Tick the trials you like and copy a ready-made email to the Clinical Research Coordinator.
Each trial's status here comes from the rosters Moffitt's disease-group research teams keep, and it changes when they send an update. Public registries are updated by sponsors and can trail what is happening at an individual site.
For 41 of our 113 active trials,
the public registry does not match our roster.
Total scope:
113 active trials
(Early Therapeutics, GI, Thoracic, Head & Neck) checked against ClinicalTrials.gov on 13 Oct 2026
Trials on hold at Moffitt, but the registry lists them as recruiting.
(Impact: False leads and coordinator calls about trials that cannot take patients.)
Trials open at Moffitt, but Moffitt is not listed as a site.
(Impact: Eligible patients may never be offered the trial.)
Trials open at Moffitt, but the registry lists them as not recruiting.
(Impact: Eligible patients may never be offered the trial.)
Concrete case: NCT06625775 (BREAKER-101)
Listed as “RECRUITING” on ClinicalTrials.gov at Moffitt.
Our internal roster: “SUSPENDED due to interim analysis.”
Registries remain the reference for eligibility criteria and protocol details. Confirm availability with the trial’s Clinical Research Coordinator.
